• Dec. 11, 2023 - Puma Biotechnology Announces Phase II CLINICAL TRIAL Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer Read
• Nov. 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Nov. 2, 2023 - Puma Biotechnology Reports Third Quarter 2023 Financial Results Read
• Oct. 19, 2023 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results Read
• Oct. 14, 2023 - Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting Read
• Oct. 4, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Sept. 21, 2023 - Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the treatment of Small Cell Lung Cancer Read
• Aug. 31, 2023 - Puma Biotechnology to Present at the H.C. Wainwright 25 th Annual Global Investment Conference Read
• Aug. 8, 2023 - Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer Read
• Aug. 3, 2023 - Puma Biotechnology Reports Second Quarter Financial Results Read
• July 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2023 Financial Results Read
• June 6, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 4, 2023 - Puma Biotechnology Announces Presentation of Biomarker Findings from a Phase II Study of Alisertib with Paclitaxel versus Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer at the 2023 ASCO Annual Meeting Read
• May 5, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• May 4, 2023 - Puma Biotechnology Reports First Quarter Financial Results Read
• Apr. 20, 2023 - Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results Read
• Apr. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Mar. 14, 2023 - Puma Biotechnology Announces Publication of Phase II Clinical Trial of Alisertib in JAMA Oncology Read
• Mar. 3, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Mar. 2, 2023 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
• Feb. 28, 2023 - Puma Biotechnology to Participate in a Panel Discussion at Cowen’s 43rd Annual Health Care Read
• Feb. 16, 2023 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2022 Read
• Feb. 7, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Feb. 1, 2023 - Puma Biotechnology’s NERLYNX® Included in NCCN Clinical Practice Guidelines for the treatment of Breast Cancer with a HER2 Mutation Read
• Jan. 12, 2023 - Puma Biotechnology to Present at B. Riley Securities’ 3rd Annual Oncology Conference Read
• Jan. 11, 2023 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Jan. 9, 2023 - Puma Biotechnology Releases Updated Corporate Presentation Read

• Dec. 7, 2022 - Puma Biotechnology Presents Updated Findings from the TBCRC-022 trial at the 2022 San Antonio Breast Cancer Symposium Read
• Dec. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Nov. 3, 2022 - Puma Biotechnology Reports Third Quarter 2022 Financial Results - Raises FY 2022 NERLYNX Net Product Revenue Guidance Read
• Nov. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Oct. 27, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket trial of Neratinib in EGFR Exon 18-Mutant NSCLC at the 2022 EORTC/NCI/AACR Symposium Read
• Oct. 20, 2022 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• Oct. 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Sept. 20, 2022 - Puma Biotechnology Announces Exclusive License Agreement with Takeda for the Development and Commercialization of Alisertib, an Investigational Aurora Kinase A Inhibitor Read
• Sept. 11, 2022 - Puma Biotechnology Presents Updated Findings from the Phase II SUMMIT Basket trial of Neratinib for HER2-Mutant, Recurrent/Metastatic Cervical Cancer at the ESMO Congress 2022 Read
• Sept. 6, 2022 - Puma Biotechnology to Present at the H.C. Wainwright 24th Annual Global Investment Conference Read
• Sept. 2, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Aug. 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• Aug. 4, 2022 - Puma Biotechnology Reports Second Quarter 2022 Financial Results Read
• July 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
• July 6, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 7, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 6, 2022 - Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT trial at the ASCO 2022 Annual Meeting Read
• June 4, 2022 - Puma Biotechnology Presents Final Results from the Biliary tract Cohort of the Phase 2 SUMMIT ‘Basket’ trial of Neratinib at the ASCO 2022 Annual Meeting Read
• May 26, 2022 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting Read
• May 11, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• May 5, 2022 - Puma Biotechnology Reports First Quarter 2022 Financial Results Read
• April 27, 2022 - Puma Biotechnology Announces Publication of Neratinib Abstract Titles for the 2022 ASCO Annual Read
• April 21, 2022 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
• April 5, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 10, 2022 - Puma Biotechnology Announces $10 Million Private Placement Read
• March 7, 2022 - Puma Biotechnology to Participate in Breast Cancer Panel at Cowen’s Annual Health Care Read
• March 4, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 3, 2022 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
• February 16, 2022 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Result Read
• February 3, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• January 20, 2022 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• January 12, 2022 - Puma Biotechnology’s NERLYNX® Included in Two Important NCCN Clinical Practice Guideline Updates for the treatment of Breast Cancer Read
• January 10, 2022 - Puma Biotechnology Releases Updated Corporate Presentation Read
• January 4, 2022 - Puma Biotechnology to Present at the H.C. Wainwright BioConnect Conference Read

• December 10, 2021 - Puma Biotechnology Presents Updates from the SUMMIT trial at the 2021 SABCS Annual Meeting Read
• December 3, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• November 23, 2021 - Puma Biotechnology Announces U.S Patent Term Extension for NERLYNX® (neratinib) Read
• November 20, 2021 - Puma Biotechnology Presents Data from the Neratinib Arm of the INSIGhT trial at the 2021 SNO Annual Meeting Read
• November 19, 2021 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Read
• November 4, 2021 - Puma Biotechnology Reports Third Quarter 2021 Financial Results Read
• October 21, 2021 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• October 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• September 21, 2021 - Puma Biotechnology to Present at the Cantor Virtual Global Healthcare Conference Read
• September 7, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• September 7, 2021 - Puma Biotechnology to Present at the H.C. Wainwright 23rd Annual Global Investment Conference Read
• August 6, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• August 5, 2021 - Puma Biotechnology Reports Second Quarter 2021 Financial Results Read
• July 26, 2021 - Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital Read
• July 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
• July 15, 2021 - NCCN Announces Selected Projects to Study Neratinib in Collaboration with Puma Biotechnology, Inc. Read
• July 2, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• July 1, 2021 - FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer Read
• June 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 4, 2021 - Puma Biotechnology Presents Data Comparing Findings from the Phase II CONTROL trial with the Neratinib Arm of the Phase III ExteNET trial at the ASCO 2021 Annual Meeting Read
• June 4, 2021 - Puma Biotechnology Presents Data from the EGFR Exon 18-mutant NSCLC Cohort of the Phase II SUMMIT trial at the 2021 ASCO Annual Meeting Read
• June 4, 2021 - Puma Biotechnology Presents Data from the Phase III ExteNET trial in Early Stage HER2-Positive Breast Cancer Patients at the Virtual 2021 ASCO Annual Meeting Read
• May 19, 2021 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2021 ASCO Annual Meeting Read
• May 6, 2021 - Puma Biotechnology Reports First Quarter 2021 Financial Results Read
• May 4, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• April 22, 2021 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
• April 13, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 8, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 4, 2021 - Puma Biotechnology to Present at the Barclays Global Healthcare Conference Read
• March 2, 2021 - Puma Biotechnology to Present at the H.C. Wainwright Global Life Sciences Conference Read
• February 25, 2021 - Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China Read
• February 25, 2021 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
• February 11, 2021 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2020 Financial Results Read
• February 9, 2021 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• January 29, 2021 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT trial of Neratinib for EGFR Exon 18-Mutated, Metastatic Non-Small Cell Lung Cancer at WCLC 2020 Read
• January 19, 2021 - Puma Biotechnology to Present at the B. Riley Oncology Investor Conference Read
• January 15, 2021 - Puma Biotechnology Presents Interim Results from the Biliary tract Cancers Cohort of the Phase II SUMMIT “Basket” trial of Neratinib at ASCO GI Read
• January 5, 2021 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read
• January 4, 2021 - Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference Read

• December 11, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• December 11, 2020 - Puma Biotechnology Presents Efficacy and Safety Outcomes from the Phase III NALA trial at the 2020 SABCS Read
• December 9, 2020 - Puma Biotechnology Presents Final Overall Survival Analysis from the Phase III ExteNET trial at the 2020 SABCS Read
• December 9, 2020 - Puma Biotechnology Presents Updated Results from the Phase II SUMMIT trial of Neratinib for HER2-Mutant, HR-Positive Metastatic Breast Cancer at SABCS 2020 Read
• December 2, 2020 - Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted Read
• November 17, 2020 - Puma Biotechnology to Present Neratinib Data at the San Antonio Breast Cancer Symposium (SABCS) Read
• November 6, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• November 5, 2020 - Puma Biotechnology Reports Third Quarter 2020 Financial Results Read
• November 5, 2020 - Puma Biotechnology Announces Interim Results from the Phase II SUMMIT trial of Neratinib for EGFR Exon 18 Mutated, Metastatic Non-Small Cell Lung Cancer Read
• November 3, 2020 - Puma Biotechnology to Present at the Credit Suisse 29th Annual Virtual Healthcare Conference Read
• October 22, 2020 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• October 15, 2020 - NCCN Oncology Research Program and Puma Biotechnology, Inc. Collaborate to Study Neratinib in Various Cancers Read
• October 5, 2020 - Puma Biotechnology Announces Publication of Overall Survival Results from Phase III ExteNET trial Evaluating Neratinib in HER2-Positive, Hormone Receptor-Positive, Early Stage Breast Cancer Read
• October 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• September 8, 2020 - Puma Biotechnology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Read
• September 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• August 19, 2020 - Puma Biotechnology Announces Publication of Interim Results of Phase II CONTROL trial in Annals of Oncology Read
• August 10, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• August 6, 2020 - Puma Biotechnology Reports Second Quarter 2020 Financial Results Read
• July 27, 2020 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT trial Evaluating Neratinib in HER2-Mutant, Metastatic Cervical Cancers Read
• July 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
• July 16, 2020 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Malaysia for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage HER2-Positive Breast Cancer Read
• July 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 2, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• May 8, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• May 7, 2020 - Puma Biotechnology Reports First Quarter 2020 Financial Results Read
• May 7, 2020 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Marketing Approval in Mainland China for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage HER2-Positive Breast Cancer Read
• May 6, 2020 - Puma Biotechnology to Present at the BofA Securities Health Care Conference 2020 Read
• April 30, 2020 - Puma Biotechnology and Bixink Therapeutics Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in South Korea Read
• April 23, 2020 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
• April 3, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 25, 2020 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• March 5, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• February 28, 2020 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference Read
• February 26, 2020 - Puma Biotechnology Receives U.S. FDA Approval of Supplemental New Drug Application for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
• February 20, 2020 - Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results Read
• February 7, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• February 5, 2020 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2019 Financial Results Read
• January 13, 2020 - Puma Biotechnology Releases Slides to be Presented at the J.P. Morgan Healthcare Conference Read
• January 9, 2020 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• January 7, 2020 - Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference Read

• December 16, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• December 13, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2019 SABCS Read
• December 12, 2019 - PlasmaMATCH trial Shows Neratinib Activity in ERBB2 (HER2) Mutant Metastatic Breast Cancer Read
• December 11, 2019 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2019 San Antonio Breast Cancer Symposium Read
• December 2, 2019 - Puma Biotechnology Licensing Partner Specialised Therapeutics Receives Marketing Approval in Singapore for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read
• December 2, 2019 - Puma Biotechnology Amends License Agreement with Pierre Fabre to Include Additional Countries Read
• November 6, 2019 - Puma Biotechnology Reports Third Quarter 2019 Financial Results Read
• November 5, 2019 - Puma Biotechnology Licensing Partner CANbridge Pharmaceuticals Receives Registration Approval in Hong Kong for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive HER2-Positive Breast Cancer Read
• November 4, 2019 - Puma Biotechnology to Present at the Credit Suisse Healthcare Conference Read
• October 23, 2019 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• October 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• October 2, 2019 - FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• September 25, 2019 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read
• September 11, 2019 - Puma Biotechnology Announces U.S. FDA Acceptance of Supplemental New Drug Application for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
• September 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• September 4, 2019 - Puma Biotechnology Licensing Partner Pint Pharma Receives Marketing Authorization for NERLYNX® (neratinib) for Extended Adjuvant treatment of Early Stage Hormone Receptor Positive, HER2-Positive Breast Cancer Read
• September 3, 2019 - Puma Biotechnology to Present at the H.C. Wainwright 21st Annual Global Investment Conference Read
• September 3, 2019 - FDA Grants Orphan Drug Designation to Puma Biotechnology’s NERLYNX® for the treatment of Breast Cancer Patients with Brain Metastases Read
• August 8, 2019 - Puma Biotechnology Reports Second Quarter 2019 Financial Results Read
• August 6, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• July 25, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• July 24, 2019 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
• July 16, 2019 - Puma Biotechnology’s Licensing Partner Knight Therapeutics Receives Regulatory Approval Read
• July 3, 2019 - Puma Biotechnology Presents Interim Results from the Biliary tract Cohort of its Phase II SUMMIT Basket trial of Neratinib at the ESMO World Congress on Gastrointestinal Cancer 2019 Read
• July 1, 2019 - Puma Biotechnology Submits a Supplemental New Drug Application to U.S. FDA for Neratinib to treat HER2-Positive Metastatic Breast Cancer Read
• June 5, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• June 4, 2019 - Puma Biotechnology Presents Results from Phase III NALA trial of Neratinib in Patients with HER2 Positive Metastatic Breast Cancer at the ASCO 2019 Annual Meeting Read
• June 2, 2019 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the ASCO 2019 Annual Meeting Read
• May 29, 2019 - Puma Biotechnology to Present at Jefferies 2019 Global Healthcare Conference Read
• May 9, 2019 - Puma Biotechnology Reports First Quarter 2019 Financial Results Read
• May 8, 2019 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2019 Read
• May 3, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• April 25, 2019 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
• April 9, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• April 4, 2019 - Puma Biotechnology Expands Cohorts in Phase II SUMMIT trial of Neratinib in Cancer Patients with Tumors with Activating EGFR or HER2 Mutations Read
• April 1, 2019 - Puma Biotechnology and Pierre Fabre Enter into Exclusive License Agreement to Develop and Commercialize NERLYNX® (neratinib) in Europe Read
• March 28, 2019 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for AACR Annual Meeting 2019 Read
• March 18, 2019 - Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• March 18, 2019 - Puma Biotechnology Presents Interim Results from the Phase II SUMMIT trial of Neratinib for HER2 (ERBB2) Mutant, Metastatic Cervical Cancer at the Society of Gynecologic Oncology (SGO) 2019 Annual Meeting Read
• March 14, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• March 5, 2019 - Puma Biotechnology to Present at Cowen’s Annual Health Care Conference Read
• February 28, 2019 - Puma Biotechnology Reports Fourth Quarter and Full Year 2018 Financial Results Read
• February 15, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• February 13, 2019 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read
• February 4, 2019 - Puma Biotechnology Announces Litigation Victory with Jury’s Decision Read
• January 11, 2019 - Puma Biotechnology and Knight Therapeutics Enter into Exclusive License Agreement to Commercialize NERLYNX® (neratinib) in Canada Read
• January 3, 2019 - Puma Biotechnology to Present at J. P. Morgan Healthcare Conference Read
• January 2, 2019 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read

• December 17, 2018 - Puma Biotechnology Announces Top Line Results of the Phase III NALA trial of Neratinib in Patients with HER2-Positive Metastatic Breast Cancer Read
• December 17, 2018 - Puma - NALA Top Line Results - Final EMBARGO Read
• December 11, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• December 10, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• December 6, 2018 - Puma Biotechnology Presents Results of Patient Reported Outcomes in Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
• December 6, 2018 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of Neratinib for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
• December 6, 2018 - Puma Biotechnology Presents Results from the Hormone Receptor Positive Subgroup in Phase III ExteNET trial of Neratinib for HER2-Amplified, Early Stage Breast Cancer at the 2018 San Antonio Breast Cancer Symposium Read
• December 3, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• November 7, 2018 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
• November 1, 2018 - Puma Biotechnology Reports Third Quarter 2018 Financial Results Read
• October 18, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• October 10, 2018 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• October 2, 2018 - Puma Biotechnology's Licensing Partner CANbridge Pharmaceutical Submits New Drug Application for NERLYNX® (neratinib) in China Read
• September 20, 2018 - Puma Biotechnology to Present at Cantor Global Healthcare Conference Read
• September 6, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• September 4, 2018 - European Commission Grants Marketing Authorisation for Puma Biotechnology's NERLYNX® (neratinib) for Extended Adjuvant treatment of Hormone Receptor Positive HER2-Positive Early Stage Breast Cancer Read
• August 9, 2018 - Puma Biotechnology Reports Second Quarter 2018 Financial Results Read
• July 31, 2018 - Puma Biotechnology Files New Drug Submission for NERLYNX® in Canada Read
• July 26, 2018 - Puma Biotechnology to Host Conference Call to Discuss Second Quarter Financial Results Read
• July 17, 2018 - Puma Biotechnology and Strata Oncology Announce Collaboration to Accelerate Enrollment in Neratinib HER2 Mutation Basket Study (SUMMIT trial) Read
• June 29, 2018 - Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• June 26, 2018 - Puma Biotechnology Announces Results of CHMP Reexamination of MAA for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• June 2, 2018 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 trial of PB272 in Combination with trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2018 ASCO Annual Meeting Read
• May 30, 2018 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read
• May 9, 2018 - Puma Biotechnology Reports First Quarter 2018 Financial Results Read
• May 8, 2018 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference 2018 Read
• April 25, 2018 - Puma Biotechnology to Host Conference Call to Discuss First Quarter Financial Results Read
• April 3, 2018 - Puma Biotechnology and Pint Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Latin America Read
• April 2, 2018 - NCCN Guidelines for Central Nervous System Cancers Include NERLYNX® (neratinib) in Combination with Capecitabine or Paclitaxel as treatment Options for Patients with Breast Cancer Brain Metastases Read
• March 6, 2018 - Puma Biotechnology to Present at Cowen's Annual Healthcare Conference Read
• March 1, 2018 - Puma Biotechnology Reports Fourth Quarter and Full Year 2017 Financial Results Read
• February 23, 2018 - Puma Biotechnology Receives Results of CHMP Formal Decision for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• February 15, 2018 - Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results Read
• February 7, 2018 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Read
• February 1, 2018 - Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Greater China Read
• January 31, 2018 - Puma Biotechnology Announces Publication of Results from Phase II SUMMIT 'Basket' trial Evaluating Neratinib in HER2 and HER3 Mutant Cancers - Data published online today in Nature - Read
• January 30, 2018 - Puma Biotechnology and Medison Pharma Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Israel Read
• January 29, 2018 - Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) Read
• January 23, 2018 - Puma Biotechnology Announces Results of CHMP Oral Explanation for Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read

• December 14, 2017 - Puma Biotechnology Added to NASDAQ Biotechnology Index Read
• December 13, 2017 - Puma Biotechnology Announces Meeting of Scientific Advisory Group on Oncology in Europe to Review Neratinib for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• December 12, 2017 - Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer Read
• December 11, 2017 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Patent Claims for Extended Adjuvant treatment Upheld Read
• December 6, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of Neratinib in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2017 San Antonio Breast Cancer Symposium Read
• November 22, 2017 - Puma Biotechnology and Specialised Therapeutics Asia Enter into Exclusive Licensing Agreement to Commercialize NERLYNX® (neratinib) in Australia, New Zealand and South East Asia Read
• November 13, 2017 - Puma Biotechnology’s 5-Year Analysis of Phase III ExteNET Study Published Online in The Lancet Oncology Data Demonstrates Continued Benefit from Neratinib after 5 years in Extended Adjuvant HER2-Positive Breast Cancer Read
• November 9, 2017 - Puma Biotechnology Reports Third Quarter 2017 Financial Results Results include the initial sales of NERLYNX® in the U.S. Read
• November 8, 2017 - Puma Biotechnology to Present at Stifel Healthcare Conference Read
• November 2, 2017 - Puma Biotechnology Secures $100 Million Term Loan from Silicon Valley Bank and Oxford Finance Read
• October 31, 2017 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
• October 26, 2017 - Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results Read
• September 18, 2017 - Puma Biotechnology to Present at Cantor Fitzgerald Healthcare Conference Read
• September 8, 2017 - Puma Biotechnology Presents 5-Year Analysis of Phase III ExteNET trial in Extended Adjuvant HER2-Positive Breast Cancer at ESMO 2017 Congress Data Demonstrates Continued Benefit from Neratinib after 5 years Read
• August 31, 2017 - Puma Biotechnology to Participate in Panel Discussion at Citi’s Biotech Conference Read
• August 30, 2017 - Puma Biotechnology Announces Publication of Abstracts for ESMO 2017 Phase III ExteNET trial in Early Stage HER2-Positive Breast Cancer Read
• August 25, 2017 - Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) Read
• August 9, 2017 - Puma Biotechnology Reports Second Quarter 2017 Financial Results Read
• August 2, 2017 - Puma Biotechnology Receives Day-180 List of Outstanding Issues from Committee for Medicinal Products for Human Use (CHMP) Read
• July 31, 2017 - Puma Announces Availability of NERLYNX™ (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in the United States Read
• July 17, 2017 - U.S. Food and Drug Administration Approves Puma’s NERLYNX™ (neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• July 6, 2017 - Puma Biotechnology Completes Targeted Enrollment in Neratinib Phase III Metastatic Breast Cancer Trial Read
• June 3, 2017 - Puma Biotechnology Announces Positive PB272 Phase II Data from TBCRC 022 trial in Patients with HER2-Positive Metastatic Breast Cancer with Brain Metastases at the 2017 ASCO Annual Meeting Read
• May 31, 2017 - Puma Biotechnology to Present at the Jefferies 2017 Healthcare Conference Read
• May 24, 2017 - Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib Read
• May 22, 2017 - Puma Biotechnology Announces Posting of FDA Oncologic Drugs Advisory Committee Briefing Documents for Neratinib Meeting Read
• May 17, 2017 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2017 ASCO Annual Meeting Read
• May 10, 2017 - Puma Biotechnology Reports First Quarter 2017 Financial Results Read
• May 9, 2017 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2017 Health Care Conference Read
• April 17, 2017 - Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• April 4, 2017 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of PB272 in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting Read
• April 2, 2017 - Puma Biotechnology Presents Results from the Phase II SUMMIT trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting Read
• April 2, 2017 - Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 trial of PB272 in Combination with trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting Read
• April 2, 2017 - Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers Read
• March 2, 2017 - Puma Biotechnology to Present at Cowen’s Health Care Conference Read
• March 1, 2017 - Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results Read
• March 1, 2017 - Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 Read
• March 1, 2017 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 Read
• February 14, 2017 - Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference Read
• February 8, 2017 - Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Read
• January 6, 2017 - Puma Biotechnology Expands Cohort in Phase II SUMMIT trial of PB272 in HER2 Mutation-Positive Cancer Patients Read
• January 3, 2017 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read

• December 19, 2016 - Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Ticker symbol to remain PBYI Read
• December 8, 2016 - Puma Biotechnology Presents Interim Results of Phase II CONTROL trial of PB272 in Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
• December 7, 2016 - Puma Biotechnology Presents Results of Biomarker Analysis of Phase II trial of PB272 in Neoadjuvant treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
• December 7, 2016 - Puma Biotechnology Presents Interim Results of Phase II trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Read
• December 6, 2016 - Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States Read
• November 14, 2016 - Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS) Read
• November 9, 2016 - Puma Biotechnology Reports Third Quarter 2016 Financial Results Read
• October 31, 2016 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
• October 25, 2016 - Puma Biotechnology Closes $172 Million Public Offering of Common Stock Read
• October 21, 2016 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Share Read
• October 19, 2016 - Puma Biotechnology Prices Public Offering of Common Stock Read
• October 18, 2016 - Puma Biotechnology Announces Proposed Public Offering of Common Stock Read
• September 20, 2016 - Puma Biotechnology Announces U.S. FDA Acceptance of New Drug Application for PB272 (Neratinib) for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• August 22, 2016 - Puma Biotechnology Announces European Medicines Agency Validation of Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe Read
• August 9, 2016 - Puma Biotechnology Reports Second Quarter 2016 Financial Results Read
• July 21, 2016 - Puma Biotechnology Submits New Drug Application for PB272 (Neratinib) to U.S. FDA for Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer Read
• July 21, 2016 - Puma Biotechnology Announces Interim 5-Year Disease Free Survival Data from Phase III trial of PB272 (Neratinib) in Extended Adjuvant HER2-Positive Early Stage Breast Cancer (ExteNET trial) Read
• July 7, 2016 - Puma Biotechnology Announces I-SPY 2 Phase II Study of Neratinib Published in The New England Journal of Medicine Read
• June 27, 2016 - Puma Biotechnology Submits Marketing Authorization Application for PB272 (Neratinib) as Extended Adjuvant treatment of HER2-Positive Early Stage Breast Cancer in Europe Read
• June 5, 2016 - Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting Read
• May 18, 2016 - Puma Biotechnology Announces Publication of Neratinib Abstract for the 2016 ASCO Annual Meeting Read
• May 17, 2016 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
• May 10, 2016 - Puma Biotechnology Reports First Quarter 2016 Financial Results Read
• May 4, 2016 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference Read
• April 20, 2016 - Puma Biotechnology’s Neratinib Featured in Poster Presentations at the AACR Annual Meeting 2016 Read
• April 14, 2016 - Puma Biotechnology’s NEfERT-T Phase II Study Published Online in JAMA Oncology Read
• March 28, 2016 - Puma Biotechnology Updates Timeline for Filing New Drug Application NDA Filing Currently Anticipated Mid-2016 Read
• March 18, 2016 - Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2016 Read
• March 2, 2016 - Puma Biotechnology to Present at Cowen’s Health Care Conference Read
• February 29, 2016 - Puma Biotechnology Reports Fourth Quarter and Full Year 2015 Financial Results Read
• February 17, 2016 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets Global Healthcare Conference Read
• February 16, 2016 - Puma Biotechnology Announces the Conclusion and Final Results of Eshelman’s Consent Solicitation Read
• February 11, 2016 - Puma Biotechnology’s ExteNET Phase III Study Published Online in The Lancet Oncology Read
• February 3, 2016 - Puma Biotechnology to Participate in Fireside Chat at Leerink Partners Global Healthcare Conference Read
• January 8, 2016 - Puma Biotechnology Shareholders Overwhelmingly Reject Eshelman’s Consent Solicitation Read
• January 4, 2016 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read

• December 30, 2015 - Third Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
• December 29, 2015 - Second Leading Independent Proxy Advisory Firm Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
• December 23, 2015 - ISS Recommends That Puma Biotechnology Shareholders Reject Eshelman's Consent Solicitation by REVOKING CONSENT on Puma's BLUE Consent Revocation Card Read
• December 18, 2015 - Puma Biotechnology Expands Third Cohort in Phase II trial of PB272 in HER2 Mutation Positive Cancer Patients Read
• December 16, 2015 - Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea Read
• December 11, 2015 - Puma Biotechnology Presents 3-Year Disease Free Survival Data from Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) at the 2015 San Antonio Breast Cancer Symposium Read
• December 10, 2015 - Puma Biotechnology Presents Interim Results of Phase II trial of PB272 for ERBB2 Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2015 San Antonio Breast Cancer Symposium Read
• December 10, 2015 - Puma Biotechnology Announces Results of Phase II trial of PB272 in Neoadjuvant treatment of HER2-Positive Locally Advanced Breast Cancer Read
• November 30, 2015 - Puma Biotechnology Provides Update from Meeting with European Medicines Agency Read
• November 13, 2015 - Puma Biotechnology to Present Data at the San Antonio Breast Cancer Symposium (SABCS) Read
• November 9, 2015 - Puma Biotechnology Reports Third Quarter 2015 Financial Results Read
• November 3, 2015 - Puma Biotechnology to Present at Credit Suisse Healthcare Conference Read
• September 26, 2015 - Puma Biotechnology Announces Presentation of Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) in Centrally Confirmed HER2-Positive Early Stage Breast Cancer Patients Read
• September 10, 2015 - Puma Biotechnology Announces Publication of PB272 in HER2 Non-Amplified Metastatic Breast Cancer with a HER2 mutation Read
• August 10, 2015 - Puma Biotechnology Reports Second Quarter 2015 Financial Results Read
• June 4, 2015 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read
• June 11, 2015 - Puma Biotechnology Announces Phase III trial of PB272 in Extended Adjuvant Breast Cancer (ExteNET trial) Demonstrates Statistically Significant Improvement in Disease Free Survival Read
• May 27, 2015 - Puma Biotechnology to Present at Jefferies 2015 Healthcare Conference Read
• May 13, 2015 - Puma Biotechnology Announces Publication of Abstracts for the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting Read
• May 12, 2015 - Puma Biotechnology to Participate in Fireside Chat at UBS Global Healthcare Conference Read
• May 11, 2015 - Puma Biotechnology Reports First Quarter 2015 Financial Results Read
• May 6, 2015 - Puma Biotechnology to Present at Bank of America Merrill Lynch Health Care Conference Read
• April 30, 2015 - Puma Biotechnology to Present at Deutsche Bank Health Care Conference Read
• April 14, 2015 - Puma Biotechnology Expands Cohort in Phase II trial of PB272 in HER2 Mutation Positive Cancer Patients Read
• March 10, 2015 - Puma Biotechnology Initiates Phase II trial of PB272 in Early Stage HER2-Positive Breast Cancer Read
• March 2, 2015 - Puma Biotechnology Reports Fourth Quarter and Full Year 2014 Financial Results Read
• February 24, 2015 - Puma Biotechnology to Present at Cowen Health Care Conference Read
• February 18, 2015 - Puma Biotechnology to Participate in Fireside Chat at RBC Capital Markets’ Global Healthcare Read
• February 5, 2015 - Puma Biotechnology to Present at Leerink Global Healthcare Conference Read
• January 27, 2015 - Puma Biotechnology Closes $218 Million Public Offering of Common Stock Read
• January 22, 2015 - Puma Biotechnology Announces Underwriters’ Full Exercise of Option to Purchase Additional Shares Read
• January 21, 2015 - Puma Biotechnology Prices Public Offering of Common Stock Read
• January 20, 2015 - Puma Biotechnology Announces Proposed Public Offering Read
• January 5, 2015 - Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Read

• December 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CtrC-AACR San Antonio Breast Cancer Symposium Read
• December 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application -NDA Filing Currently Anticipated for Q1 2016 Read
• November 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II trial in HER2 Positive Metastatic Breast Cancer (NEfERTT trial) Read
• November 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference Read
• November 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results Read
• September 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II trial in HER2 Mutated Non-Small Cell Lung Cancer Read
• September 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014 Read
• August 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results Read
• July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 trial in Adjuvant Breast Cancer (ExteNET trial) Read
• July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer Read
• June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference Read
• June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting Read
• May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference Read
• May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
• May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read
• May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results Read
• May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference Read
• April 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL Read
• March 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference Read
• March 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 trIAL at AACR Annual Meeting 2014 Read
• March 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results Read
• February 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference Read
• February 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock Read
• February 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares Read
• February 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock Read
• February 6, 2014 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Read

• December 17, 2013 - Puma Biotechnology to Hold Conference Call to Provide Update on PB272 Clinival Trials in Patients with HER2 Mutations Read
• December 4, 2013 - Puma Biotechnology Reports Positive Top Line Data from I-SPY 2 TRIAL Read
• November 12, 2013 - Puma Biotechnology Reports Third Quarter 2013 Financial Results Read
• October 4, 2013 - Puma Biotechnology Initiates Phase II trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read
• September 4, 2013 - Puma Biotechnology to Present at Stifel Healthcare Conference Read
• August 6, 2013 - Puma Biotechnology Reports Second Quarter 2013 Financial Results Read
• June 24, 2013 - Puma Biotechnology to Join Russell 3000 Index Read
• June 7, 2013 - Puma Biotechnology Initiates Phase III trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
• June 5, 2013 - Puma Biotechnology to Present at Goldman Sachs Healthcare Conference Read
• May 29, 2013 - Puma Biotechnology to Present at Jefferies Global Healthcare Conference Read
• May 17, 2013 - Puma Biotechnology Comment on trading Activity Read
• May 14, 2013 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
• May 9, 2013 - Puma Biotechnology Reports First Quarter 2013 Financial Results Read
• May 8, 2013 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2013 Health Care Conference Read
• April 1, 2013 - Puma Biotechnology Reports Fourth Quarter and Full Year 2012 Financial Results Read
• February 26, 2013 - Puma Biotechnology to Present at Cowen Health Care Conference Read
• February 20, 2013 - Puma Biotechnology Announces Agreement with FDA on Special Protocol Assessment for Phase III trial of PB272 (Neratinib) in HER2-Positive Metastatic Breast Cancer Patients Read
• February 6, 2013 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read

• December 7, 2012 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CtrC-AACR San Antonio Breast Cancer Symposium Read
• November 14, 2012 - Puma Biotechnology Reports Third Quarter 2012 Financial Results Read
• November 7, 2012 - Puma Biotechnology to Present at Lazard Healthcare Conference Read
• October 24, 2012 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock Read
• October 22, 2012 - Puma Biotechnology Announces Underwriters' Full Exercise of Overallotment Option, Increasing Total Offering Size to $138 Million Read
• October 18, 2012 - Puma Biotechnology Announces Upsizing and Pricing of $120 Million Public Offering of Common Stock Read
• September 12, 2012 - Puma Biotechnology to Present at UBS Global Life Sciences Conference Read
• August 29, 2012 - Puma Biotechnology to Present at Stifel Nicolaus 2012 Healthcare Conference Read
• August 14, 2012 - Puma Biotechnology Reports Second Quarter 2012 Financial Results Read
• August 7, 2012 - Puma Biotechnology to Present at Wedbush PacGrow Life Sciences Conference Read
• June 2, 2012 - Puma Biotechnology Presents Positive PB272 Clinical Data at ASCO 2012 Annual Meeting Read
• May 30, 2012 - Puma Biotechnology to Present at Jefferies Healthcare Conference Read
• May 17, 2012 - Puma Biotechnology to Present Clinical Data on PB272 at ASCO 2012 Annual Meeting Read
• May 9, 2012 - Puma Merrill Lynch Health Care Conference Read
• April 16, 2012 - Puma Biotechnology Cleared for Quotation on OTCBB and OTC LINK Read
• February 28, 2012 - Puma Biotechnology to Present at Cowen Health Care Conference Read
• February 9, 2012 - Puma Biotechnology to Present at Leerink Swann Global Healthcare Conference Read
• January 4, 2012 - Puma Biotechnology to Present at 30th Annual J.P. Morgan Healthcare Conference Read

• December 9, 2011 - Puma Biotechnology Announces Positive PB272 (Neratinib) Phase II Data at CTRC-AACR San Antonio Breast Cancer Symposium Read
• November 23, 2011 - Puma Biotechnology Announces Completion of Private Placement Read
• October 5, 2011 - Puma Biotechnology Announces Licensing Agreement with Pfizer Read